Journal
CELL DEATH AND DIFFERENTIATION
Volume 13, Issue 8, Pages 1339-1350Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.cdd.4401992
Keywords
apoptosis; programmed cell death; BCL-2; BH3 domain; alpha-helix; structure; small molecule; peptide; targeted therapy
Categories
Funding
- NHLBI NIH HHS [K08HL074049] Funding Source: Medline
Ask authors/readers for more resources
The discovery of B-cell lymphoma-2 (BCL-2) over 20 years ago revealed a new paradigm in cancer biology: the development and persistence of cancer can be driven by molecular roadblocks along the natural pathway to cell death. The subsequent identification of an expansive family of BCL-2 proteins provoked an intensive investigation of the interplay among these critical regulators of cell death. What emerged was a compelling tale of guardians and executioners, each participating in a molecular choreography that dictates cell fate. Ten years into the BCL-2 era, structural details defined how certain BCL-2 family proteins interact, and molecular targeting of the BCL-2 family has since become a pharmacological quest. Although many facets of BCL-2 family death signaling remain a mechanistic mystery, small molecules and peptides that effectively target BCL-2 are eliminating the roadblock to cell death, raising hopes for a medical breakthrough in cancer and other diseases of deregulated apoptosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available